

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in this application.

Listing of Claims:

1. (Currently Amended) A method of treating ~~diabetes a-vascular, muscle, hepatic, pancreatic, or neural disease~~, said method comprising the step of administering to a patient in need thereof a pluripotent cell or a progeny cell derived therefrom prepared from human umbilical cord blood or, placental blood, or a blood sample from a newborn human, wherein said pluripotent cell (a) expresses SH2, SH3, SH4, CD13, CD29, CD49e, CD54, and CD90 antigen markers; and (b) does not express CD14, CD31, CD34, CD45, CD49d, or CD106 antigen markers; and (c) is capable of differentiating into one or more of a mesenchymal pluripotent cell, a hematopoietic pluripotent cell, a neural pluripotent cell, or an endothelial pluripotent cell.

2.-6. (Cancelled)

7. (Currently Amended) The method of claim 1, wherein said method comprises administering said cell to effect organ regeneration of pancreatic islet cells.

8.-47. (Cancelled)

48. (New) The method of claim 1, wherein said method comprises administering a plurality of said cells.

49. (New) The method of claim 1, wherein said cell is administered in a pharmaceutically acceptable carrier.

50. (New) The method of claim 49, wherein the pharmaceutically acceptable

carrier is selected from the group consisting of saline, a gel, a hydrogel, a sponge, and a matrix.

51. (New) The method of claim 1, wherein said cell is administered by infusion into the blood stream of said patient.

52. (New) The method of claim 51, wherein said infusion comprises intracoronary, retrograde venous, intraventricular, intracerebroventricular, cerebrospinal, and intracranial infusion.

53. (New) The method of claim 51, wherein said infusion is repeated one or more times.

54. (New) The method of claim 1 further comprising administering to said patient an agent that induces said cell to differentiate into a pancreatic islet cell *in vivo*.